It is thus suggested that mifepristone prevents pathological obesity due to adipocyte hypertrophy, probably owing to its enhancement of the expression and secretion of adiponectin, which is attributed to the improvement of insulin resistance induced by a high-fat diet. Here, ADIPOQ is linked to Insulin resistance.